TORONTO, March 23 /CNW/ - Bradmer Pharmaceuticals Inc., a
biopharmaceutical company dedicated to the development and commercialization
of cancer therapies, today announced the appointment of Jean Bourgouin, M.D.,
as Vice President of Medical Affairs. Dr. Bourgouin has more than 25 years of
clinical development and management experience in the pharmaceutical sector in
Canada. Prior to joining Bradmer, Dr. Bourgouin spent eight years as the Vice
President of Scientific Affairs at Aventis Pharma Canada (formerly Hoechst
Marion Roussel). Dr. Bourgouin will operate out of the Company's new office in
"Dr. Bourgouin brings a combination of technical experience, which
includes work as a practicing physician, and knowledge of the pharmaceutical
sector from his work with Aventis that will strengthen our management
capabilities," said Dr. Alan Ezrin, Chief Operating Officer of Bradmer. "The
addition of Dr. Bourgouin demonstrates our ability to attract talent and build
a world class team dedicated to the commercialization of new therapies for
cancer patients. Dr. Bourgouin will play a key role in the implementation of
our Phase III pivotal trial of Neuradiab for the treatment of glioblastoma
As Vice President of Scientific Affairs at Aventis Pharma Canada, Dr.
Bourgouin oversaw all stages of clinical development in Canada as well as
registration and market access implementing health economics, health
management and professional education strategies. Dr. Bourgouin also held
senior management roles with Rhone-Poulenc Rorer Canada. A graduate of
Université de Montréal where he acquired a doctorate diploma in medicine, Dr.
Bourgouin went on to become Associate Professor in the Pharmacology
Department. Dr. Bourgouin received his B.A. from Collège Jean de Brébeuf, his
M.Sc. in Pharmacology from Université de Montréal, and is a licensed member of
the Medical Council of Canada.
Neuradiab is a monoclonal antibody, conjugated to radioactive iodine,
used to treat glioblastoma multiforme (GBM), the most common and most advanced
form of brain cancer. Neuradiab delivers tumor-killing radiation specifically
to residual brain tumor cells after surgery, with minimal impact on normal
brain tissue. During the course of development at Duke University, over US$60
million in research grants and related support has produced a series of Phase
I and Phase II clinical trials on Neuradiab and closely related technologies.
Approximately 200 brain cancer patients, including over 160 with GBM, have
been treated with the Neuradiab therapy regimen, and survival benefits have
significantly exceeded historical controls in each completed trial.
Each year up to 30,000 new cases of GBM are diagnosed in world's seven
largest healthcare markets. The current standard of care for GBM patients is
surgical resection followed by radiation and temozolomide. GBM tumors
typically have infiltrating edges that are very difficult to completely remove
with surgery. The Neuradiab therapy is delivered directly into the surgical
resection cavity in a separate procedure after the initial surgery. Neuradiab
delivers a concentrated level of radiation specifically to the remaining
cancer cells by targeting tenascin. Tenascin is a protein over-expressed in
99% of GBM cells but absent from normal brain cells.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. To date, over US$60 million in grants
and related support has driven research and development of the licensed
treatment, which has been delivered to over 200 patients with promising
results and has completed Phase II clinical trials at Duke University. Bradmer
is currently in the process of organizing a Phase III pivotal clinical trial
of the licensed treatment. Neuradiab has been granted Orphan Drug Status by
both the U.S. Food and Drug Administration and the European Medicines Agency.
Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Bradmer Pharmaceuticals Inc., Mr. Brian
Brohman, Chief Financial Officer, Phone: (416) 361-6058, E-mail:
email@example.com, Internet: www.bradmerpharma.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail: firstname.lastname@example.org